What are the opening hours?

Monday 9am - 5:30pm Tuesday 9am - 5:30pm Wednesday 9am - 5:30pm Thursday 9am - 5:30pm Friday 9am - 5:30pm

Association of Cancer Care Centers

Home
United States
North Bethesda, MD
Association of Cancer Care Centers

Founded in 1974, ACCC is a powerful network of more than 45,000 multidisciplinary professionals from over 1,700 provider organizations nationwide.

The Association of Community Cancer Centers (ACCC) promotes the entire continuum of quality cancer care for our patients and our communities. Since 1974, ACCC has been helping oncology professionals adapt to the complex changes of delivering quality cancer care. ACCC members rely on the Association to bring them information on cancer program management, reimbursement issues, legislative and regula

tory changes at the state and national levels, community cancer program standards, NCI-funded community clinical research, hospital alliances and physician relationships, and more. More than 28,000 cancer care professionals from more than 2,000 hospitals and practices nationwide are affiliated with ACCC. It is estimated that 65 percent of the nation's cancer patients are treated by a member of ACCC.

09/09/2026

Last call: Join ACCC's virtual Office Hours on Collaborative Care Models on Thursday, September 10, 2026, at 12:00 PM EDT. Register now: https://hubs.li/Q04x0L160.

Bring your questions and real-world challenges to an open discussion with experts and peers in psychosocial oncology and social work. Explore practical approaches to implementation and sustainability while exchanging ideas about strengthening integrated, team-based cancer care.

Featuring: Jesse Fann, MD, MPH of Fred Hutch; William Pirl, MD, MPH of Memorial Sloan Kettering; Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC of Providence Cancer Institute - Oregon; and Courtney Bitz, LICSW, OSW-C, ACHP-SW of Dana-Farber Cancer Institute.

Thank you to our partners, Association of Oncology Social Work (AOSW) and APOS American Psychosocial Oncology Society.

08/28/2026

Explore key considerations for treating chronic lymphocytic leukemia (CLL) after covalent Bruton's tyrosine kinase (BTK) inhibitor therapy. Download a tip sheet now: https://hubs.li/Q04vJ6x_0.

Review strategies for distinguishing disease progression from treatment intolerance, selecting subsequent therapies, and safely transitioning treatment. The resource also highlights the importance of molecular profiling, disease kinetics, comorbidities, and clinical trial opportunities.

Thank you to our expert faculty from University of Colorado Denver and The Ohio State University.

08/27/2026

Dermatologic toxicities from EGFR inhibitor therapy can significantly affect a patient's quality of life and treatment adherence—yet approaches to prevention and management still vary widely across cancer programs.

To help close that gap, ACCC brought together patient advocates and providers across the multidisciplinary care team for a new video series: Supportive Care Strategies for Dermatologic Toxicities Related to EGFR Inhibitor Therapies.

The series covers:
- The current landscape of EGFR inhibitor therapies
- Proactive strategies for managing skin toxicities
- Workflows for coordinated, interdisciplinary care
- Treatment decision-making factors driven by patient quality of life.

View now: https://hubs.ly/Q04vx40W0.

08/25/2026

ACCC remembers Harold P. Freeman, MD, pioneer of patient navigation and a lifelong advocate for health equity. His work helped shape ACCC's patient navigation and financial navigation educational programming and continues to play a part in the patient-centered care impacting countless lives today.

Read our full statement:https://bit.ly/4gi3DPj.

08/15/2026

🎧 "Low risk" doesn't mean low stakes. In this episode, Amy DeZern, MD, MHS (Sidney Kimmel Comprehensive Cancer Center at Jefferson) and Christin Blair DeStefano, MD, FACP (Walter Reed National Military Medical Center) unpack why that label can quietly mislead patients — and what it takes to keep care on track once treatment begins.

They dig into the molecular complexity behind modern MDS classification, why quality-of-life check-ins every 2-3 months matter more than clinicians often realize, and how easy it is to put a "stable" patient on autopilot.

🔗 Listen here: https://hubs.ly/Q04t52QB0 or wherever you get your podcasts.

08/13/2026

As advanced practice providers ( ) have become increasingly embedded within the health care system, their role as part of the multidisciplinary care team has become essential in expanding access to care. The newest issue of explores the value of a quad leadership model that incorporates advanced practice leadership and provides APP institutional representation, strengthens retention, and supports staff resilience as a result: https://hubs.ly/Q04sXQlF0.

08/07/2026

Help patients with chronic lymphocytic leukemia (CLL) overcome Medicare Part D coverage barriers. Register now: https://hubs.li/Q04sgd250.

Changes to Part D policies can affect access to CLL therapies, creating treatment delays and additional administrative burden for teams. Join ACCC and CLL Society Inc. on August 12 to examine the evolving Part D landscape, effective approaches to payer challenges, and strengthen patient access to appropriate treatment.

08/06/2026

Proposed Medicare payment and policy changes for CY 2027 could have important implications for your cancer program. Register for the ACCC Virtual ORM now: https://hubs.li/Q04s2Ffd0.

Receive timely guidance on the proposed CY 2027 Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective Payment System (HOPPS) rules. Hear from oncology policy, coding, reimbursement, and experts from ACCC, St. Luke's University Health Network, and Revenue Cycle Coding Strategies as they discuss emerging coverage risks and the evolving policy landscape affecting .

Free for members. Can't attend? Register now to receive recorded sessions on demand.

07/31/2026

Build a strategy for bispecific antibody (BsAb) delivery that aligns with your program's capabilities. Explore ACCC's new implementation package now: https://hubs.li/Q04rsvG10.

🔹 Implementing BsAbs: Practical Framework for Care Delivery
🔸 Delivery Models for Administering T-Cell–Engaging BsAbs

As BsAbs become part of routine cancer care, these complementary resources can help your multidisciplinary team evaluate organizational readiness, determine the right care delivery approach, and prepare for safe, coordinated implementation.

Developed in partnership with APSHO, Hematology/Oncology Pharmacy Association - HOPA, and Lymphoma Research Foundation.

07/15/2026

Bispecific antibodies (BsAbs) are an emerging and fast-developing area of immunotherapy, particularly in the treatment of hematologic malignancies. However, access to this therapy remains limited, particularly for Veterans. Administrative hurdles and challenging adverse events have slowed adoption of in the US Department of Veterans Affairs (VA).

In this episode, speaks with Nicholas Burwick, MD, President of the Association of VA Hematology/Oncology (AVAHO); Associate Professor, Division of Hematology and Oncology at the University of Washington Department of Medicine; and a Hematologist at VA Puget Sound Health Care System. Buriwck shares how his VA site tackled these challenges and made BsAbs available to its patient population through a collaborative hub-and-spoke model.

Listen here: https://hubs.ly/Q04pCMgY0 or wherever you get your podcasts.

Address

North Bethesda, MD

Opening Hours

Monday	9am - 5:30pm
Tuesday	9am - 5:30pm
Wednesday	9am - 5:30pm
Thursday	9am - 5:30pm
Friday	9am - 5:30pm

Telephone

(301)9849496

Website

http://www.accc-cancer.org/

Alerts

Be the first to know and let us send you an email when Association of Cancer Care Centers posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Association of Cancer Care Centers:

Want your business to be the top-listed Health & Beauty Business in North Bethesda?